These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
632 related items for PubMed ID: 26841376
21. Whole-body positron emission tomography with 18F-fluorodeoxyglucose is an effective method to detect extra-pelvic recurrence in uterine sarcomas. Sung PL, Chen YJ, Liu RS, Shieh HJ, Wang PH, Yen MS, Wen KC, Shen SH, Lai CR, Yuan CC. Eur J Gynaecol Oncol; 2008; 29(3):246-51. PubMed ID: 18592788 [Abstract] [Full Text] [Related]
23. A retrospective study comparing contrast-enhanced computed tomography with 18F-FDG-PET/CT in the early follow-up of patients with retroperitoneal sarcomas. Niccoli-Asabella A, Altini C, Notaristefano A, Merenda N, Altieri ML, Stabile-Ianora AA, Fanelli M, Rubini G. Nucl Med Commun; 2013 Jan; 34(1):32-9. PubMed ID: 23111380 [Abstract] [Full Text] [Related]
24. Clinical utility of F-18 FDG PET/CT in recurrent breast carcinoma. Manohar K, Mittal BR, Senthil R, Kashyap R, Bhattacharya A, Singh G. Nucl Med Commun; 2012 Jun; 33(6):591-6. PubMed ID: 22334135 [Abstract] [Full Text] [Related]
25. Differentiation of FDG-avid loco-regional recurrent and compromised benign lesions after surgery for breast cancer with dual-time point F-18-fluorodeoxy-glucose PET/CT scan. Suga K, Kawakami Y, Hiyama A, Matsunaga N. Ann Nucl Med; 2009 Jun; 23(4):399-407. PubMed ID: 19452249 [Abstract] [Full Text] [Related]
27. Utility of positron emission tomography/computed tomography (PET/CT) imaging in the evaluation of sarcomas: A systematic review. Lim HJ, Johnny Ong CA, Tan JW, Ching Teo MC. Crit Rev Oncol Hematol; 2019 Nov; 143():1-13. PubMed ID: 31449981 [Abstract] [Full Text] [Related]
28. F18-FDG-PET/CT in the evaluation of patients with suspected recurrent or persistent locally advanced cervical carcinoma. Cetina L, Serrano A, Cantú-de-León D, Pérez-Montiel D, Estrada E, Coronel J, Hernández-Lucio M, Dueñas-González A. Rev Invest Clin; 2011 Nov; 63(3):227-35. PubMed ID: 21888286 [Abstract] [Full Text] [Related]
33. Role of delayed-time-point imaging during abdominal and pelvic cancer screening using FDG-PET/CT in the general population. Naganawa S, Yoshikawa T, Yasaka K, Maeda E, Hayashi N, Abe O. Medicine (Baltimore); 2017 Nov; 96(46):e8832. PubMed ID: 29145346 [Abstract] [Full Text] [Related]
39. [Is FDG TEP CT practice changing in the management of sarcomas in adults?]. Kogay M, Thariat J, Benisvy D, Dufour M, Gastaud L, Saada E, Iannessi A, Thyss A. Bull Cancer; 2016 Sep; 103(9):735-42. PubMed ID: 27452925 [Abstract] [Full Text] [Related]